In consequence, survivin is addressed in cancer therapy by molecular antagonists like antisense oligonucleotides, siRNA, or hammerhead ribozymes, as well as small molecules or cancer immunotherapeutics [67]. This evidence concerns the gene BIRC5 and cancer.